Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the decision by regulatory authorities in the United States of America to disallow further use of the Evusheld monoclonal antibody product; and what steps they will take to ensure appropriate prophylaxis and treatment against COVID-19 for vulnerable immunodeficient and immunocompromised patients.

The Antivirals and Therapeutics Taskforce engages with other nations to share learning on the use, deployment and evaluation of therapeutics and antivirals. Evusheld (tixagevimab and cilgavimab) has a conditional marketing authorisation in the United Kingdom for the pre-exposure prophylaxis of COVID-19 and has been referred to the National Institute for Health and Care Excellence (NICE) to make recommendations for the National Health Service on whether it should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness.

The final outcome of NICE’s evaluation on the use of Evusheld as a pre-exposure prophylactic treatment against COVID-19 is expected in April 2023.